Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

NIH 2OTHER 1NETWORK 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Prostatic Neoplasms 90Breast Neoplasms 87Melanoma 86Multiple Myeloma 69Carcinoma, Non-Small-Cell Lung 63Leukemia, Myeloid, Acute 62Lymphoma 59Brain Neoplasms 57Glioblastoma 55Ovarian Neoplasms 51Neoplasms 51Carcinoma, Renal Cell 49Lymphoma, Non-Hodgkin 47Fallopian Tube Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 45Sarcoma 44Gliosarcoma 43Neoplasm Metastasis 39Lung Neoplasms 36Carcinoma, Hepatocellular 35Precursor Cell Lymphoblastic Leukemia-Lymphoma 34Pancreatic Neoplasms 33Glioma 33Lymphoma, Large B-Cell, Diffuse 32Uterine Cervical Neoplasms 31Hematologic Neoplasms 31Colonic Neoplasms 31Small Cell Lung Carcinoma 29Myelodysplastic Syndromes 28Rhabdomyosarcoma 27

Interventions

trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Paclitaxel 1Letrozole 1Doxorubicin 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Has results × Cystadenocarcinoma, Serous × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

NCT00551070 2020-12-03

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡